|
Synonyms: Compound 204 [WO2023129667]
Compound class:
Synthetic organic
Comment: Faldoritinib is the INN for a tyrosine kinase inhibitor that was included in WHO INN Proposed List 135 (July 2026). It is described as an antineoplastic agent. The structure is claimed in a number of patents for activity as a fms related receptor tyrosine kinase 3 (FLT3) inhibitor [3]. In the absence of a declared company code-to-structure, we predict that faldoritinib might be the INN for Biomea's orally bioavailable, covalent (irreversible) FLT3 inhibitor clinical lead BMF-500 [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| Bioactivity Comments |
| Faldoritinib is an equipotent inhibitor of wild-type FLT3 and FLT3-ITD which is a common internal tandem duplication genetic mutation found in around a quarter of acute mlyeloid leukemia patients [3]. It Does not alter KIT activity [2].Faldoritinib |
| Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||